Clinical predictors of response in metastatic germ cell tumors

G. Taylor, D. J. Perry, R. D. Knight, N. A. Dawson, Steven Skoog, D. G. McLeod

Research output: Contribution to journalArticle

Abstract

Twenty-two patients with bulky, metastatic germ cell tumors were treated with cyclophosphamide, vinblastine, dactinomycin, bleomycin, and cisplatin (VAB) alternating with VP-16 and vincristine (VV). The overall complete response rate after chemotherapy with or without surgical excision of residual tissue was 63% (14 of 22 patients) with a median survival of 46 months. Five patients are dead of disease progression and three are alive beyond 3 years with only residual radiographic abnormalities. A retrospective analysis of prognostic variables (numbers of sites of disease, tumor marker levels) using two previously published prognosis formulas demonstrated a good correlation between prognostic variables (numbers of sites of disease, tumor marker levels) and the clinical assessment of prognosis based on tumor bulk and tumor marker level. Nevertheless, individual patients with other, unknown prognostic features may be incorrectly evaluated using either established formulas of clinical assessment of tumor bulk.

Original languageEnglish (US)
Pages (from-to)217-221
Number of pages5
JournalCancer
Volume62
Issue number1
StatePublished - 1988
Externally publishedYes

Fingerprint

Germ Cell and Embryonal Neoplasms
Tumor Biomarkers
Vinblastine
Bleomycin
Dactinomycin
Vincristine
Etoposide
Cyclophosphamide
Cisplatin
Disease Progression
Neoplasms
Drug Therapy
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Taylor, G., Perry, D. J., Knight, R. D., Dawson, N. A., Skoog, S., & McLeod, D. G. (1988). Clinical predictors of response in metastatic germ cell tumors. Cancer, 62(1), 217-221.

Clinical predictors of response in metastatic germ cell tumors. / Taylor, G.; Perry, D. J.; Knight, R. D.; Dawson, N. A.; Skoog, Steven; McLeod, D. G.

In: Cancer, Vol. 62, No. 1, 1988, p. 217-221.

Research output: Contribution to journalArticle

Taylor, G, Perry, DJ, Knight, RD, Dawson, NA, Skoog, S & McLeod, DG 1988, 'Clinical predictors of response in metastatic germ cell tumors', Cancer, vol. 62, no. 1, pp. 217-221.
Taylor G, Perry DJ, Knight RD, Dawson NA, Skoog S, McLeod DG. Clinical predictors of response in metastatic germ cell tumors. Cancer. 1988;62(1):217-221.
Taylor, G. ; Perry, D. J. ; Knight, R. D. ; Dawson, N. A. ; Skoog, Steven ; McLeod, D. G. / Clinical predictors of response in metastatic germ cell tumors. In: Cancer. 1988 ; Vol. 62, No. 1. pp. 217-221.
@article{c96b4d923d07431f80b9cfe656496858,
title = "Clinical predictors of response in metastatic germ cell tumors",
abstract = "Twenty-two patients with bulky, metastatic germ cell tumors were treated with cyclophosphamide, vinblastine, dactinomycin, bleomycin, and cisplatin (VAB) alternating with VP-16 and vincristine (VV). The overall complete response rate after chemotherapy with or without surgical excision of residual tissue was 63{\%} (14 of 22 patients) with a median survival of 46 months. Five patients are dead of disease progression and three are alive beyond 3 years with only residual radiographic abnormalities. A retrospective analysis of prognostic variables (numbers of sites of disease, tumor marker levels) using two previously published prognosis formulas demonstrated a good correlation between prognostic variables (numbers of sites of disease, tumor marker levels) and the clinical assessment of prognosis based on tumor bulk and tumor marker level. Nevertheless, individual patients with other, unknown prognostic features may be incorrectly evaluated using either established formulas of clinical assessment of tumor bulk.",
author = "G. Taylor and Perry, {D. J.} and Knight, {R. D.} and Dawson, {N. A.} and Steven Skoog and McLeod, {D. G.}",
year = "1988",
language = "English (US)",
volume = "62",
pages = "217--221",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - Clinical predictors of response in metastatic germ cell tumors

AU - Taylor, G.

AU - Perry, D. J.

AU - Knight, R. D.

AU - Dawson, N. A.

AU - Skoog, Steven

AU - McLeod, D. G.

PY - 1988

Y1 - 1988

N2 - Twenty-two patients with bulky, metastatic germ cell tumors were treated with cyclophosphamide, vinblastine, dactinomycin, bleomycin, and cisplatin (VAB) alternating with VP-16 and vincristine (VV). The overall complete response rate after chemotherapy with or without surgical excision of residual tissue was 63% (14 of 22 patients) with a median survival of 46 months. Five patients are dead of disease progression and three are alive beyond 3 years with only residual radiographic abnormalities. A retrospective analysis of prognostic variables (numbers of sites of disease, tumor marker levels) using two previously published prognosis formulas demonstrated a good correlation between prognostic variables (numbers of sites of disease, tumor marker levels) and the clinical assessment of prognosis based on tumor bulk and tumor marker level. Nevertheless, individual patients with other, unknown prognostic features may be incorrectly evaluated using either established formulas of clinical assessment of tumor bulk.

AB - Twenty-two patients with bulky, metastatic germ cell tumors were treated with cyclophosphamide, vinblastine, dactinomycin, bleomycin, and cisplatin (VAB) alternating with VP-16 and vincristine (VV). The overall complete response rate after chemotherapy with or without surgical excision of residual tissue was 63% (14 of 22 patients) with a median survival of 46 months. Five patients are dead of disease progression and three are alive beyond 3 years with only residual radiographic abnormalities. A retrospective analysis of prognostic variables (numbers of sites of disease, tumor marker levels) using two previously published prognosis formulas demonstrated a good correlation between prognostic variables (numbers of sites of disease, tumor marker levels) and the clinical assessment of prognosis based on tumor bulk and tumor marker level. Nevertheless, individual patients with other, unknown prognostic features may be incorrectly evaluated using either established formulas of clinical assessment of tumor bulk.

UR - http://www.scopus.com/inward/record.url?scp=0023935402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023935402&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 217

EP - 221

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -